IOR researchers suggest that androgen-deprivation treatments for prostate cancer could protect men from COVID-19

The so-called "androgen-deprivation" treatments used in prostate cancer therapy may have a protective effect against COVID-19. A study conducted by the Istitute of Oncology Research (IOR, affiliated to USI) based on health data obtained from the Veneto region in Italy has observed a lower risk of developing the coronavirus disease for men subject to this type of therapy. The study, performed in co...
More

Tiziano Bernasocchi awarded “PhD in Life Sciences” from the University of Lausanne

Tiziano Bernasocchi, molecular biologist in the Prostate Cancer Genome group of Prof. Jean-Philippe Theurillat, successfully defended his Ph.D. on April 21st, 2020, from the University of Lausanne. He presented the work entitled: Dual Functions of SPOP and ERG Dictate Androgen Therapy Responses in Prostate Cancer.  The research work elucidates an enigmatic finding of comprehensive prostate canc...
More

Geniver El Tekle received the “PhD in Life Sciences” from the University of Lausanne

Geniver El Tekle successfully defended her Ph.D. thesis at the Institute of Oncology Research (IOR) in Bellinzona on April 20th, 2020. Her thesis entitled “ Functional Characterization and Therapeutic Implications of SPOP Mutations in Endometrial and Prostate Cancer” was carried out in the Functional Cancer Genomics group directed by Prof. Jean-Philippe Theurillat at the IOR.   The thesis focus...
More

IOR paves the way for the clinical development of a therapy against prostate cancer metastasis

An international group of researchers, led by Andrea Alimonti, Group Leader at the Institute of Oncology Research (IOR, affiliated to USI) and Professor at the USI Faculty of Biomedical Sciences and at ETH Zurich, has discovered a mechanism to recognise the cancer cells responsible for prostate cancer and selectively eliminate them. The study was published on April 6 by the Journal of Clinical Inv...
More

New Review on the International Journal of Molecular Sciences

The PI3K/AKT/mTOR pathway is one of the signaling cascades most commonly hijacked by cancer cells. Lymphoma cells are no exceptions. Thus, their pharmacological targeting is being extensively explored. Following their previous work with the dual PI3K/mTOR inhibitor bimiralisib (PQR309) (PMID: 29066507), Dr Chiara Tarantelli and Prof. Francesco Bertoni from IOR, together with PD Anastasios Stath...
More

Pfizer Prize 2020, awards for IOR and IRB researchers in oncology and neurology

The awards for the 29th Pfizer Prize for Research were given on Thursday, February 6, in Zurich. Among the winners were Daniela Latorre, former researcher at the Institute for Research in Biomedicine (IRB) affiliated to USI Università della Svizzera italiana and currently researcher at ETH Zurich, and Arianna Calcinotto of the Institute of Oncological Research (IOR), also affiliated to the U...
More